AL Amyloidosis Clinical Trial
Official title:
Optimize First-line Treatment for Systemic Light Chain Amyloidosis With t (11; 14)
Achievement of complete hematologic response (CHR) is vital for systemic AL amyloidosis. Currently, the CHR rate of daratumumab, bortezomib, and dexamethasone (DBD) is close to 60%. Considering that Bcl-2 inhibitor is effective for AL amyloidosis with t(11; 14) and the median hematologic onset time of DBD is 7 days. We design a a prospective study on AL amyloidosis with t(11; 14). All patients receive DBD at the beginning. Patient will receive DBD for at least 6 cycles if achieve rapid hematologic response at day 7, while other patients will receive daratumumab, venetoclax and dexamethasone.
The goal of this clinical trial is to optimize the first line treatment for systemic AL amyloidosis with t(11;14). The aim of this study is to pursue early complete hematologic response. The primary endpoint is overall complete hematologic response (CHR) rate at 6 months. Participants will be treated according to the hematologic response after 7 days. If the patient get rapid response after 7 days, he/she will receive daratumumab, venetoclax and dexamethasone (DBD) for at least 6 cycles. If the patient do not get rapid response, he/she will receive daratumumab, venetoclax and dexamethasone. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05451771 -
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
|
Phase 1/Phase 2 | |
| Completed |
NCT02574676 -
Quality of Life (QOL) Registry for Patients With AL Amyloidosis
|
||
| Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
| Active, not recruiting |
NCT05199337 -
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01758042 -
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
|
N/A | |
| Completed |
NCT01409148 -
Radioimmunoimaging of AL Amyloidosis
|
Phase 1 | |
| Active, not recruiting |
NCT04512235 -
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis
|
Phase 3 | |
| Recruiting |
NCT06383143 -
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
|
||
| Recruiting |
NCT05277493 -
A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab
|
||
| Completed |
NCT02632786 -
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
|
Phase 2 | |
| Completed |
NCT02841033 -
Daratumumab for the Treatment of Patients With AL Amyloidosis
|
Phase 1/Phase 2 | |
| Completed |
NCT04304144 -
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
|
Phase 2 | |
| Recruiting |
NCT01408225 -
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
|
||
| Recruiting |
NCT04895917 -
Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis
|
Phase 2 | |
| Terminated |
NCT02489500 -
Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib
|
Phase 3 | |
| Completed |
NCT01570387 -
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
|
Phase 1/Phase 2 | |
| Terminated |
NCT03154047 -
Study in Subjects With Light Chain (AL) Amyloidosis
|
Phase 2 | |
| Completed |
NCT03236792 -
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04392960 -
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
|
N/A | |
| Recruiting |
NCT05898646 -
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
|
Phase 2 |